Solabia has acquired a majority stake in BioActor, a specialist in the development and commercialisation of clinically evaluated polyphenols extracted from edible plants and fruits and used by leading food supplement brands worldwide
Solabia has announced that it has acquired a majority stake in polyphenols expert BioActor B.V.
Founded in 2011 and located on the Maastricht Health Campus, BioActor is an innovation leader in the development and commercialisation of clinically evaluated polyphenols extracted from edible plants and fruits and used by leading food supplement brands worldwide.
Thanks to an in-house clinical research team with direct access to a state-of-the-art clinical research facility and a genuine passion for innovation, BioActor’s health ingredients are all first-in-class, offering supplement brands the opportunity to develop unique solutions to consumers worldwide. BioActor currently exports to more than 20 countries worldwide, serving leading brands across the nutrition and supplement industries.
We are looking forward to working with BioActor to enhance growth for current product portfolio and accelerate the development of new ingredients
Solabia is already present in the nutrition segment through original ingredients recognised for their health benefits, including Algatech’s microalgae-derived active ingredients. This strategic investment will allow Solabia to benefit from a wider range of ingredients and from BioActor’s expertise, strengthening its nutrition division positioning on this fast-growing market, as customers increasingly look for high-quality active ingredients that combine naturality with proof of efficacy.
This new partnership will also support BioActor’s continued focus on R&D and product development, as well as the expansion of its production capabilities, enabling the company to serve the increasing global demand for its products.
BioActor will become a centre of excellence for innovation and clinical research within Solabia’s nutrition division and the combination will allow both companies to benefit from the combined network and expertise, as well as to access new marketing channels and an expanded customer base.
Hans van der Saag, BioActor’s founder and CEO, retains a minority share and his role as CEO of BioActor.
Commenting on the acquisition, Jean-Baptiste Dellon, CEO of Solabia, said: “We are very impressed by BioActor’s dynamic team and innovation engine, and we are very pleased to welcome them to Solabia. BioActor’s pioneering R&D, impressive clinical research capabilities, market-leading product portfolio and established customer base will allow us to further strengthen our position in the nutrition and food supplement markets. We are looking forward to working with BioActor to enhance growth for current product portfolio and accelerate the development of new ingredients.”
Hans van der Saag, Founder & CEO of BioActor, added: “[The acquisition] marks a significant milestone for the company and the people behind its success, and it is an important step towards realising our mission to bring unique and clinically evaluated health ingredients to consumers worldwide. I am also thankful for the hard work and dedication of our employees. Together with Solabia, we are poised to extend the BioActor growth story as part of a larger organisation with an extensive global footprint, a shared commitment to innovation, research and development, and an unwavering focus on utilising the benefits of nutrition to elevate the health of all of us.”